The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease

Clinical and Experimental Immunology

Volumn 160, Issue 3, 2010, Pages 386-393

  Sugihara, T ^a,b   Kobori, A ^a   Imaeda, H ^a   Tsujikawa, T ^a   Amagase, K ^b   Takeuchi, K ^b   Fujiyama, Y ^a   Andoh, A ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Crohn's disease; IBD; IL 17; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; DISULFIDE; I KAPPA B KINASE ALPHA; INTERLEUKIN 17; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; DISULFIDE BOND; ENTERITIS; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; ULCERATIVE COLITIS;

ADENOVIRIDAE; COLITIS, ULCERATIVE; COLON; COMPLEMENT C3; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION; HUMANS; I-KAPPA B PROTEINS; IMIDAZOLES; INTERLEUKIN-17; INTESTINAL MUCOSA; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 77952222918     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04093.x     Document Type: Article

References (53)

1. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007 42 : 16 25. (Pubitemid 46351421)
2. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008 43 : 1 17. (Pubitemid 351324980)
3. Kobayashi T, Okamoto S, Hisamatsu T et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008 57 : 1682 1689.
4. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003 52 : 65 70. (Pubitemid 36020767)
5. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008 14 : 390 400.
6. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008 14 : 437 445. (Pubitemid 351571823)
7. Rovedatti L, Kudo T, Biancheri P et al. Differential regulation of interleukin-17 and interferon-{gamma} production in inflammatory bowel disease. Gut 2009 58 : 1629 1636.
8. Leppkes M, Becker C, Ivanov II, Hirth S et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009 136 : 257 267.
9. Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009 206 : 525 534.
10. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009 15 : 1090 1100.
11. Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008 14 : 5154 5161.
12. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm 2009 2009 : 297645.
13. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 441 : 235 238.
14. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006 126 : 1121 1133. (Pubitemid 44380299)
15. Hata K, Andoh A, Shimada M et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002 282 : G1035 44. (Pubitemid 34651610)
16. Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther 2007 114 : 94 106. (Pubitemid 46498158)
17. Toy D, Kugler D, Wolfson M et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006 177 : 36 9. (Pubitemid 43939112)
18. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004 21 : 467 476. (Pubitemid 39370503)
19. Yagi Y, Andoh A, Inatomi O, Tsujikawa T, Fujiyama Y. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol 2007 42 : 746 753. (Pubitemid 47456762)
20. Longhi MP, Harris CL, Morgan BP, Gallimore A. Holding T cells in check - a new role for complement regulators? Trends Immunol 2006 27 : 102 108. (Pubitemid 43221977)
21. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004 5 : 981 986. (Pubitemid 41057714)
22. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009 388 : 621 625. (Pubitemid 44328063)
23. Uematsu S, Akira S. Immune responses of TLR5(+) lamina propria dendritic cells in enterobacterial infection. J Gastroenterol 2009 44 : 803 811.
24. Morgan BP. The complement system. In : Morgan BP, ed. Complement: clinical aspects and relevance to disease.
25. Andoh A, Fujiyama Y, Bamba T, Hosoda S. Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J Immunol 1993 151 : 4239 4247. (Pubitemid 23298757)
26. Andoh A, Fujiyama Y, Sakumoto H et al. Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas. Clin Exp Immunol 1998 111 : 477 483. (Pubitemid 28160888)
27. Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990 322 : 1345 1349. (Pubitemid 20154477)
28. Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 1989 30 : 361 366. (Pubitemid 19091163)
29. Johswich K, Martin M, Bleich A et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 2009.
30. Rector A, Lemey P, Laffut W et al. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun 2001 2 : 323 328. (Pubitemid 33674244)
31. Deguchi Y, Andoh A, Inatomi O et al. Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 2005 16 : 605 608.
32. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989 298 : 82 6. (Pubitemid 19032930)
33. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979 77 : 843 846.
34. Mahida YR, Beltinger J, Makh S et al. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol 1997 273 : G1341 8. (Pubitemid 127797990)
35. Okuno T, Andoh A, Bamba S et al. Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 2002 37 : 317 324. (Pubitemid 34194818)
36. Zweibaum A, Pinto M, Chevalier G et al. Enterocytic differentiation of a subpopulation of the human colon tumor cell line HT-29 selected for growth in sugar-free medium and its inhibition by glucose. J Cell Physiol 1985 122 : 21 9. (Pubitemid 15177223)
37. de Bruijn MH, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci U S A 1985 82 : 708 712. (Pubitemid 15142747)
38. Yao Z, Painter SL, Fanslow WC et al. IL-17: a novel cytokine derived from T cells. J Immunol 1995 155 : 5483 5486.
39. Obara H, Takayanagi A, Hirahashi J et al. Overexpression of truncated IkappaBalpha induces TNF-alpha-dependent apoptosis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000 20 : 2198 2204.
40. Yasumoto H, Kim S, Zhan Y et al. Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther 2001 8 : 1682 1689. (Pubitemid 34030701)
41. Andoh A, Fujiyama Y, Hata K et al. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999 118 : 23 9. (Pubitemid 29479779)
42. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995 270 : 27489 27494.
43. Favata MF, Horiuchi KY, Manos EJ et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998 273 : 18623 18632. (Pubitemid 28334795)
44. Cuenda A, Rouse J, Doza YN et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995 364 : 229 233.
45. Andoh A, Zhang Z, Inatomi O et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005 129 : 969 984. (Pubitemid 41242688)
46. Andoh A, Shioya M, Nishida A et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009 183 : 687 695.
47. Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006 55 : 1774 1780. (Pubitemid 44893577)
48. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999 277 : C1 9.
49. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999 277 : C183 201.
50. Fan JD, Wagner BL, McDonnell DP. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endocrinol 1996 10 : 1605 1616.
51. Moon MR, Parikh AA, Pritts TA et al. Complement component C3 production in IL-1beta-stimulated human intestinal epithelial cells is blocked by NF-kappaB inhibitors and by transfection with ser 32/36 mutant IkappaBalpha. J Surg Res 1999 82 : 48 55.
52. Vik DP, Amiguet P, Moffat GJ et al. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 1991 30 : 1080 1085.
53. Andoh A, Yasui H, Inatomi O et al. Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol 2005 40 : 802 810. (Pubitemid 41349236)